Vincristine

Vincristine

Clinical data
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	Exclusively intravenous
ATC code	L01CA02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	n/a
Protein binding	~75%
Metabolism	Hepatic
Elimination half-life	19 to 155 hours
Excretion	Mostly biliary, 10% in urine
Identifiers
CAS Number	57-22-7
PubChem CID	5978
DrugBank	APRD00495
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C46H56N4O10
Molar mass	824.958 g/mol

WikiDoc Resources for Vincristine
Articles
Most recent articles on Vincristine Most cited articles on Vincristine Review articles on Vincristine Articles on Vincristine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Vincristine Images of Vincristine Photos of Vincristine Podcasts & MP3s on Vincristine Videos on Vincristine
Evidence Based Medicine
Cochrane Collaboration on Vincristine Bandolier on Vincristine TRIP on Vincristine
Clinical Trials
Ongoing Trials on Vincristine at Clinical Trials.gov Trial results on Vincristine Clinical Trials on Vincristine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Vincristine NICE Guidance on Vincristine NHS PRODIGY Guidance FDA on Vincristine CDC on Vincristine
Books
Books on Vincristine
News
Vincristine in the news Be alerted to news on Vincristine News trends on Vincristine
Commentary
Blogs on Vincristine
Definitions
Definitions of Vincristine
Patient Resources / Community
Patient resources on Vincristine Discussion groups on Vincristine Patient Handouts on Vincristine Directions to Hospitals Treating Vincristine Risk calculators and risk factors for Vincristine
Healthcare Provider Resources
Symptoms of Vincristine Causes & Risk Factors for Vincristine Diagnostic studies for Vincristine Treatment of Vincristine
Continuing Medical Education (CME)
CME Programs on Vincristine
International
Vincristine en Espanol Vincristine en Francais
Business
Vincristine in the Marketplace Patents on Vincristine
Experimental / Informatics
List of terms related to Vincristine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Vincristine (Oncovin®), also known as leurocristine, is a vinca alkaloid from the Madagascar periwinkle (Catharanthus roseus, formerly Vinca rosea and hence its name). It is a mitotic inhibitor, and is used in cancer chemotherapy.

Mode of action

Tubulin is a structural protein which polymerises to form microtubules. The cell cytoskeleton and mitotic spindle, amongst other things, are made of microtubules. Vincristine binds to tubulin dimers, inhibiting assembly of microtubule structures. Disruption of the microtubules arrests mitosis in metaphase. The vinca alkaloids therefore affect all rapidly dividing cell types including cancer cells, but also intestinal epithelium and bone marrow.

Uses

Vincristine, injected intravenously only, is used in various types of chemotherapy regimens. Its main uses are in non-Hodgkin's lymphoma as part of the chemotherapy regimen CHOP, Hodgkin's lymphoma as part of MOPP or COPP, or the less popular Stanford V chemotherapy regimen, and in acute lymphoblastic leukemia. It is occasionally used as an immunosuppressant, e.g. in thrombotic thrombocytopenic purpura (TTP).

Side effects

The main side-effects of vincristine are peripheral neuropathy, hyponatremia, and constipation.

Peripheral neuropathy can be severe, hence reason to avoid, reduce, or stop the use of vincristine. One of the first symptoms of peripheral neuropathy is foot drop: a person with a family history of foot drop and/or Charcot-Marie-Tooth disease (CMT) may benefit from genetic testing for CMT before taking vincristine.

Accidental injection of vinca alkaloids into the spinal canal (intrathecal administration) is highly dangerous, with a mortality rate approaching 100%. The medical literature documents cases of ascending paralysis due to massive encephalopathy and spinal nerve demyelination, accompanied by intractable pain, almost uniformly leading to death; a handful of survivors were left with devastating neurological damage with no hope of recovery. Rescue treatments consist of washout of the cerebrospinal fluid and administration of protective medications.

History

Having been used as a folk remedy for centuries, studies in the 1950s revealed that C. roseus contained 70 alkaloids, many of which are biologically active. While initial studies for its use in diabetes mellitus were disappointing, the discovery that it caused myelosuppression (decreased activity of the bone marrow) led to its study in mice with leukemia, whose lifespan was prolonged by the use of a vinca preparation. Treatment of the ground plant with Skelly-B defatting agent and an acid benzene extract led to a fraction termed "fraction A". This fraction was further treated with aluminium oxide, chromatography, trichloromethane, benz-dichloromethane and separation by pH to yield vincristine.

Vincristine was approved by the United States Food and Drug Administration (FDA) in July 1963 as Oncovin. The drug was initially marketed by Eli Lilly and Company.

Suppliers

Three generic drug makers supply vincristine in the United States - APP, Mayne, and Sicor (Teva).

See also

• Rosy Periwinkle

External links

• Vincristine chemotherapy
• Vincristine and vinblastine
• Description and Natural History of the Periwinkle
• The Boger Route to (-)-Vindoline